OBIO (Orchestra BioMed Holdings, Inc. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by OBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | David P Hochman | See Remarks | Buy | — | — |
| 2026-09-02 | Darren Sherman | See Remarks | Sell | — | — |
| 2026-08-28 | Joshua Aiello | Principal Accounting Officer | F | — | — |
| 2026-08-28 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2026-08-28 | Darren Sherman | See Remarks | MIXED | — | — |
| 2026-08-14 | John Prosper Mack | Director | F | — | — |
| 2026-08-14 | Chris Cleary | Director | F | — | — |
| 2026-08-14 | Eric S Fain | Director | F | — | — |
| 2026-08-14 | David Pacitti | Director | F | — | — |
| 2026-08-04 | Darren Sherman | See Remarks | Sell | — | — |
| 2026-07-02 | Darren Sherman | See Remarks | Sell | — | — |
| 2026-06-25 | Jason Aryeh | Director | A | — | — |
| 2026-06-25 | John Prosper Mack | Director | MIXED | — | — |
| 2026-06-25 | Eric S Fain | Director | MIXED | — | — |
| 2026-06-25 | Pamela Ann Connealy | Director | A | — | — |
| 2026-06-25 | David Pacitti | Director | MIXED | — | — |
| 2026-06-25 | Chris Cleary | Director | F | — | — |
| 2026-06-12 | David P Hochman | See Remarks | F | — | — |
| 2026-06-12 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2026-06-02 | Darren Sherman | See Remarks | Sell | — | — |
| 2026-06-02 | David P Hochman | See Remarks | Buy | — | — |
| 2026-05-29 | Darren Sherman | See Remarks | F | — | — |
| 2026-05-29 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2026-05-20 | Jason Aryeh | Director | Buy | — | — |
| 2026-05-19 | Jason Aryeh | Director | Buy | — | — |
| 2026-05-19 | David P Hochman | See Remarks | Buy | — | — |
| 2026-05-18 | Eric S Fain | Director | Buy | — | — |
| 2026-04-29 | RODERICK WONG | 10%+ Owner | MIXED | — | — |
| 2026-03-27 | Darren Sherman | See Remarks | F | — | — |
| 2026-03-27 | Joshua Aiello | Principal Accounting Officer | F | — | — |
| 2026-03-27 | David P Hochman | See Remarks | F | — | — |
| 2026-03-16 | David P Hochman | See Remarks | Buy | — | — |
| 2026-02-13 | Darren Sherman | See Remarks | A | — | — |
| 2026-02-13 | Andrew Lawrence Taylor | Chief Financial Officer | A | — | — |
| 2026-02-13 | David P Hochman | See Remarks | A | — | — |
| 2026-02-13 | Joshua Aiello | Principal Accounting Officer | A | — | — |
| 2026-02-06 | Darren Sherman | See Remarks | A | — | — |
| 2026-02-06 | Chris Cleary | Director | F | — | — |
| 2026-01-02 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2026-01-02 | Joshua Aiello | Principal Accounting Officer | F | — | — |
| 2026-01-02 | Darren Sherman | See Remarks | F | — | — |
| 2025-12-12 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2025-12-12 | David P Hochman | See Remarks | F | — | — |
| 2025-11-26 | Darren Sherman | See Remarks | F | — | — |
| 2025-11-26 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| 2025-11-17 | David P Hochman | See Remarks | Buy | — | — |
| 2025-11-14 | David P Hochman | See Remarks | F | — | — |
| 2025-09-19 | David P Hochman | See Remarks | F | — | — |
| 2025-09-19 | Jason Aryeh | Director | Buy | — | — |
| 2025-09-19 | Andrew Lawrence Taylor | Chief Financial Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,556,063 | — |
| — | 10%+ Owner | 8,306,063 | — |
| — | 10%+ Owner | 5,292,556 | — |
| — | 10%+ Owner | 4,999,423 | — |
| — | 10%+ Owner | 1,705,705 | — |
| — | Director | 1,298,210 | — |
| — | See Remarks | 1,136,402 | — |
| — | See Remarks | 1,072,746 | — |
| — | Chief Financial Officer | 589,989 | — |
| — | See Remarks | 307,859 | — |
| — | Chief Financial Officer | 162,574 | — |
| — | See Remarks | 158,905 | — |
| — | Director | 118,118 | — |
| — | Director | 107,130 | — |
| — | Director | 66,544 | — |
| — | Director | 66,038 | — |
| — | Director | 54,750 | — |
| — | See Remarks | 42,000 | — |
| — | Director | 29,153 | — |
| — | Principal Accounting Officer | 18,441 | — |
| — | Director | 7,544 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OBIO quote page; the site-wide leaderboard is on the insider transactions hub.